Lower baseline MMP9 plasma levels correlated with better clinical response to VT1021 in patients with GBM and pancreatic cancer, suggesting that plasmatic MMP9 levels may be a predictive biomarker for VT1021. This evidence concerns the gene MMP9 and familial pancreatic carcinoma.